GlassScriptPhysician profile
Elizabeth Bowlin
NPI 1598339699
$1,432.36
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $359 · 2023: $367 · 2024: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $571.01 | 2021-2024 | Rybelsus, Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $135.44 | 2022-2024 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $132.82 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $131.08 | 2022-2024 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $123.83 | 2022-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $92.16 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $41.98 | 2024 | Krystexxa |
| Exact Sciences Corporation | $40.53 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $37.96 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.97 | 2022 | |
| Organon LLC | $31.60 | 2024 | |
| Abbvie INC. | $22.16 | 2024 | |
| Cepheid | $19.71 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Bowlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.